摘要
目的:探讨脾氨肽对小儿巨细胞病毒感染的T淋巴细胞亚群及CMV-DNA载量的影响。方法:选择我院2015年6月到2016年12月期间收治的巨细胞病毒感染患儿86例,按照随机数字法将其分为对照组和观察组,每组43例。所有患儿均接受对症支持治疗,并给予等量更昔洛韦静脉滴注治疗,在此基础上,观察组患儿口服脾氨肽治疗。比较两组患儿的治疗总有效率、不良反应发生率及治疗前后的血清CD4^+、CD8^+、CD4^+/CD8^+水平和尿CMV-DNA载量。结果:治疗后,观察组的治疗总有效率(91.49%)明显高于对照组(70.21%)(P=0.01),血清CD4^+和CD4^+/CD8^+水平明显高于对照组(P<0.01),尿CMV-DNA载量和血清CD8^+水平均明显低于对照组(P<0.01)。两组患儿的不良反应发生率比较差异无统计学意义(P>0.05)。结论:脾氨肽治疗小儿巨细胞病毒感染的临床效果较好,能有效纠正T淋巴细胞亚群失衡、降低CMV-DNA载量,且安全性高。
Objective： To explore the effect of Spleen ammonia peptide on the T lymphocyte subsets and CMV-DNA loads of in- fantile cytomegalovirus infection. Methods： 86 cases of infants with cytomegalovirus infection admitted in our hospital from June 2015 to December 2016 were chosen as the research objects and divided into the control group and the observation group according to the method of random Numbers, with 43 cases in each group. All the infants were treated by symptomatic support and given equal ganci- clovir by intravenous drip. On this basis, the observation group was given oral spleen ammonia peptide. The total effective rate, incidence of adverse reactions and evels of CD4＋, CD8＋, CD4＋/CD8＋ levels and urinary CMV-DNA loads before and after treatment were com- pared between two groups. Results： After treatment, the total effective rate of observation group （91.49%） was significantly higher than that of the control group （70.21%）（P=5.84）, the CD4＋ and CD4＋/CD8＋ levels of observation group were significantly higher than those of the control group, while the urinary CMV-DNA loads and level ofCD8＋ were significantly lower （P〈0.01）. There was no significant dif- ference in the incidence of adverse reactions between two groups（P〉0.05）. Conclusion： Spleen ammonia peptide could enhance the clini- cal efficacy in the treatment of infantile cytomegalovirus infection, which could effectively correct the T lymphocyte subsets imbalance loads, reduce the CMV-DNA with high safety.
作者
杨艳峰
石坤
陈婷婷
郭永宏
朱红枫
YANG Yan-feng1, SHI Kun1, CHEN Ting-ting1, GUO Yong-hong1, ZHU Hong-fen2(1 Department of Cardiology, Chengdu women＇s and children＇s Center Hospital, Chengdu, Sichuan, 610000, China; 2 The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, Chin)
出处
《现代生物医学进展》
CAS
2018年第5期923-926,共4页
Progress in Modern Biomedicine
基金
四川省科技攻关项目(201221056)
